Immunome, Inc is a biotechnology business based in the US. Immunome shares (IMNM) are listed on the NASDAQ and all prices are listed in US Dollars. Immunome employs 23 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Immunome
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMNM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Immunome stock price (NASDAQ: IMNM)Use our graph to track the performance of IMNM stocks over time.
Immunome shares at a glance
|Latest market close||$20.92|
|52-week range||$9.28 - $48.70|
|50-day moving average||$16.92|
|200-day moving average||$23.03|
|Wall St. target price||$36.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Immunome shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Immunome stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immunome price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||22.34%|
|3 months (2021-04-30)||-21.23%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-30.8%|
|Return on equity TTM||-92.63%|
|Market capitalisation||$189.1 million|
TTM: trailing 12 months
Shorting Immunome shares
There are currently 210,608 Immunome shares held short by investors – that's known as Immunome's "short interest". This figure is 0.9% up from 208,669 last month.
There are a few different ways that this level of interest in shorting Immunome shares can be evaluated.
Immunome's "short interest ratio" (SIR)
Immunome's "short interest ratio" (SIR) is the quantity of Immunome shares currently shorted divided by the average quantity of Immunome shares traded daily (recently around 66859.682539683). Immunome's SIR currently stands at 3.15. In other words for every 100,000 Immunome shares traded daily on the market, roughly 3150 shares are currently held short.
To gain some more context, you can compare Immunome's short interest ratio against those of similar companies.
However Immunome's short interest can also be evaluated against the total number of Immunome shares, or, against the total number of tradable Immunome shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunome's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Immunome shares in existence, roughly 20 shares are currently held short) or 0.0242% of the tradable shares (for every 100,000 tradable Immunome shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunome.
Find out more about how you can short Immunome stock.
Immunome share dividends
We're not expecting Immunome to pay a dividend over the next 12 months.
Immunome, Inc. , a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. .
Stocks similar to Immunome
Immunome in the news
Ridgewood Investments LLC Buys Immunome Inc, Vanguard Russell 1000 Value Index Fund, Fidelity Nasdaq Composite Tracking Stock, Sells Berkshire Hathaway Inc, Axos Financial Inc, Invesco S&P 500 Low Volatility ETF
38 Stocks Moving In Wednesday's Mid-Day Session
28 Stocks Moving in Wednesday's Pre-Market Session
Frequently asked questionsWhat percentage of Immunome is owned by insiders or institutions?
Currently 21.804% of Immunome shares are held by insiders and 16.984% by institutions. How many people work for Immunome?
Latest data suggests 23 work at Immunome. When does the fiscal year end for Immunome?
Immunome's fiscal year ends in December. Where is Immunome based?
Immunome's address is: 665 Stockton Drive, Exton, PA, United States, 19341 What is Immunome's ISIN number?
Immunome's international securities identification number is: US45257U1088
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert